{"ticker": {"uuid": "775f47f6-0545-4bcf-ae55-3a8e1c3a7201", "symbol": "CRDF", "name": "Cardiff Oncology Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cardiff Oncology (CRDF) Proxy filing Summary", "summary": "Cardiff Oncology (CRDF) has scheduled its annual meeting for June 11, 2026, where shareholders will vote on four key proposals: the election of six directors, the ratification of BDO USA, P.C. as auditor, an amendment to increase shares under the 2021 Equity Incentive Plan, and a", "url": "https://quartr.com/events/cardiff-oncology-crdf-proxy-filing_F9QdsfRX", "source_name": "Quartr", "published_at": "2026-07-17T07:12:10", "published_display": "17 Jul 2026 07:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQSmFmN2NJYlVWWDZRNUNIRWlDSXh0TUM1TDRFSWN6RFY3eW1SeEpoeTh6UHRMeHNHb2ZrQzhpVy1KbDBvNUF3T1AxOWpxdmVZUFRzVk5vcFFhRWFuR3VHZ1piR1kzMU9DRmp4WGxBckhRT2txaTJpVjNadGJXQWQ2alNFTENRX1ZMbU5pYlJQZ25DZHRKMXNnaGgzRDl3QWJVb3cxdk9MNlQ4OGxReXU1NDlEWTAwclFneW42YTFRYUJkZy1Z?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T20:30:22+00:00", "published_display": "16 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cardiff-oncology-insider-bought-shares-200834437.html", "source_name": "MT Newswires", "published_at": "2026-07-16T20:08:34+00:00", "published_display": "16 Jul 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) CEO adds common shares and new warrants stake", "summary": "Cardiff Oncology (CRDF) CEO Mani Mohindru purchased 34,364 common shares on July 14, 2026, at $1.455 per share and acquired an equal number of common stock purchase warrants. These transactions increased her direct holdings to 59,067 common shares and 34,364 warrants. The warrant", "url": "https://www.stocktitan.net/sec-filings/CRDF/form-4-cardiff-oncology-inc-insider-trading-activity-16e458dc03f5.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:09:42", "published_display": "16 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) director buys 687,285 shares and warrants", "summary": "Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases of 687,285 shares of common stock at $1.455 per share and an equal number of common stock purchase warrants with an exercise price of $1.33 per share, dated July 14, 2026. Following these transactions, Pa", "url": "https://www.stocktitan.net/sec-filings/CRDF/form-4-cardiff-oncology-inc-insider-trading-activity-b296479b55c2.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:09:42", "published_display": "16 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cardiff Oncology Inc For: 16 July By Investing.com", "summary": "This article provides a Form 4 filing for Cardiff Oncology Inc. for July 16, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The ar", "url": "https://ca.investing.com/news/stock-market-news/form-4-cardiff-oncology-inc-for-16-july-93CH-4738277", "source_name": "Investing.com Canada", "published_at": "2026-07-16T20:09:42", "published_display": "16 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cardiff Oncology Raises $10M for Onvansertib Regulatory Push", "summary": "Cardiff Oncology (CRDF) has raised $10 million in a registered direct offering to support regulatory discussions for its lead drug, onvansertib. The drug, an oral PLK1 inhibitor, showed promising Phase II results for RAS-mutated metastatic colorectal cancer, achieving a 72.2% obj", "url": "https://allsci.com/news/funding/public-equity-offerings/cardiff-oncology-raises-usd-10m-ahead-of-regulatory-push-for-onvansertib-in-ras-mutated-colorectal-cancer/", "source_name": "AllSci", "published_at": "2026-07-16T17:09:42", "published_display": "16 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Raises $10.05 Million in Registered Offering; Engages H.C. Wainwright", "summary": "Cardiff Oncology successfully completed a registered equity financing, raising approximately $10.05 million in gross proceeds through the sale of shares and warrants to institutional investors and insiders. The company also engaged H.C. Wainwright as its exclusive placement agent", "url": "https://www.tradingview.com/news/tradingview:ef93d043b1292:0-cardiff-oncology-raises-10-05-million-in-registered-offering-engages-h-c-wainwright/", "source_name": "TradingView", "published_at": "2026-07-16T12:40:38", "published_display": "16 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (Nasdaq: CRDF) closes $10.05M direct offering", "summary": "Cardiff Oncology (Nasdaq: CRDF) has successfully closed a direct offering totaling approximately $10.05 million. The offering involved the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 per share and warrant, with certain officers and directors also p", "url": "https://www.stocktitan.net/sec-filings/CRDF/8-k-cardiff-oncology-inc-reports-material-event-2b72b0890312.html", "source_name": "Stock Titan", "published_at": "2026-07-16T12:40:38", "published_display": "16 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (NASDAQ: CRDF) prices $10.05M share and warrant financing", "summary": "Cardiff Oncology Inc. (NASDAQ: CRDF) has priced a public offering to raise $10.05 million through the sale of common stock and accompanying warrants. The offering includes 9,293,078 shares of common stock and warrants to purchase an equal number of shares, with proceeds designate", "url": "https://www.stocktitan.net/sec-filings/CRDF/424b5-cardiff-oncology-inc-prospectus-supplement-debt-securities-6d756f94ac57.html", "source_name": "Stock Titan", "published_at": "2026-07-16T12:40:38", "published_display": "16 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Announces $10 Million Registered Direct Offering", "summary": "Cardiff Oncology, Inc. has announced a registered direct offering expected to raise approximately $10 million. The offering includes the sale of common stock and accompanying warrants to both institutional investors and certain officers and directors of the company. The net proce", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327673/0/en/Cardiff-Oncology-Announces-10-Million-Registered-Direct-Offering.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T04:09:42", "published_display": "16 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology to Raise $10 Million in Share, Warrant Sale", "summary": "Cardiff Oncology plans to raise $10 million through the sale of shares and warrants to Armistice Capital Master Fund. The company will sell 10 million shares of common stock and warrants to purchase up to 10 million shares at a price of $1.00 per share and accompanying warrant. T", "url": "https://www.moomoo.com/news/post/73012441/cardiff-oncology-to-raise-10-million-in-share-warrant-sale", "source_name": "Moomoo", "published_at": "2026-07-16T02:40:38", "published_display": "16 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital", "summary": "Cardiff Oncology announced a $10 million registered direct offering to bolster its working capital and general corporate purposes. The offering includes common stock and warrants, with participation from company officers and directors. The capital infusion will support the contin", "url": "https://finance.yahoo.com/healthcare/articles/cardiff-oncology-announces-10-million-145406378.html", "source_name": "Market source", "published_at": "2026-07-15T14:54:51", "published_display": "15 Jul 2026 14:54", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology announces $10M direct offering", "summary": "Cardiff Oncology has announced a $10 million registered direct offering. The offering is priced at a premium to the preceding 5-day average closing price of its common stock. This financial move aims to raise capital for the company.", "url": "https://www.msn.com/en-us/money/savingandinvesting/cardiff-oncology-announces-10m-direct-offering/ar-AA27Ydj7?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-07-15T12:12:35", "published_display": "15 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology prices $10M registered direct offering", "summary": "Cardiff Oncology (NASDAQ:CRDF) announced a $10 million registered direct offering, selling over 8.5 million shares and accompanying warrants at $1.05 per share and warrant. Company officers and directors are participating in the offering. The biotech firm plans to use the net pro", "url": "https://www.investing.com/news/company-news/cardiff-oncology-prices-10m-registered-direct-offering-93CH-4793172", "source_name": "Investing.com", "published_at": "2026-07-15T12:12:35", "published_display": "15 Jul 2026 12:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Seeks $10M as Some Officers and Directors Agree to Buy Shares", "summary": "Cardiff Oncology (Nasdaq: CRDF) announced a registered direct offering to raise approximately $10 million by selling 8,571,429 common shares and accompanying warrants at $1.05 per share. Separately, certain officers and directors will purchase 731,707 shares and warrants at $1.43", "url": "https://www.stocktitan.net/news/CRDF/cardiff-oncology-announces-10-million-registered-direct-n63wapgew06g.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:12:35", "published_display": "15 Jul 2026 12:12", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Cardiff Oncology, Inc. \u2013 FWB:XE7C", "summary": "The article provides a financial overview of Cardiff Oncology, Inc. (XE7C) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to EBIT forward ratio. It appears to be a stub or placeholder from TradingView, indicating where this financial metric would b", "url": "https://www.tradingview.com/symbols/FWB-XE7C/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T19:39:59", "published_display": "12 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) Noble Capital Markets Emerging Growth Virtual Investor Conference summary", "summary": "Cardiff Oncology (CRDF) summarized their Noble Capital Markets Emerging Growth Virtual Investor Conference, highlighting the promising clinical data for Onvansertib, an oral PLK1 inhibitor, in RAS-mutated metastatic colorectal cancer. The drug showed significant efficacy and tole", "url": "https://quartr.com/events/cardiff-oncology-inc-crdf-noble-capital-markets-emerging-growth-virtual-investor-conference_F9Qde7R0", "source_name": "Quartr", "published_at": "2026-07-08T14:09:28", "published_display": "08 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cardiff Oncology, Inc. \u2013 NASDAQ:CRDF", "summary": "This article provides access to the \"Price to earnings forward\" data for Cardiff Oncology, Inc. (NASDAQ: CRDF) on the TradingView platform. It highlights that the market was closed with no trades recorded at the time of viewing. The content primarily focuses on navigating to the ", "url": "https://www.tradingview.com/symbols/NASDAQ-CRDF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:13:18", "published_display": "08 Jul 2026 01:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cardiff Oncology, Inc. \u2013 TRADEGATE:XE7C", "summary": "The article displays the \"Price to earnings forward\" metric for Cardiff Oncology, Inc. (TRADEGATE:XE7C) on the TradingView platform. It indicates that the market was closed and no trades had occurred for this particular stock. The content primarily focuses on the financial data d", "url": "https://www.tradingview.com/symbols/TRADEGATE-XE7C/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T09:12:24", "published_display": "07 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cardiff Oncology, Inc. \u2013 TRADEGATE:XE7C", "summary": "This article provides financial information for Cardiff Oncology, Inc. (XE7C) on the Tradegate Exchange, specifically focusing on its enterprise value to EBIT forward. The content is presented through TradingView, a platform offering market data and financial tools. It indicates ", "url": "https://www.tradingview.com/symbols/TRADEGATE-XE7C/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T13:41:03", "published_display": "06 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cardiff Oncology, Inc. \u2013 NASDAQ:CRDF", "summary": "This page provides the \"Price to book forward\" financial metric for Cardiff Oncology, Inc. (NASDAQ: CRDF). It states the period, value, and change for this specific financial data point. The content appears to be a data-only entry from TradingView, without additional analytical t", "url": "https://www.tradingview.com/symbols/NASDAQ-CRDF/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T14:12:52", "published_display": "05 Jul 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDF - Cardiff Oncology Inc Dividends", "summary": "This article provides a detailed financial overview of Cardiff Oncology Inc. (CRDF), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short ", "url": "https://finviz.com/stock?t=CRDF&ty=dv", "source_name": "Finviz", "published_at": "2026-07-05T00:12:53", "published_display": "05 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cardiff Oncology, Inc. \u2013 NASDAQ:CRDF", "summary": "This article displays the \"Price to sales forward\" metric for Cardiff Oncology, Inc. (NASDAQ: CRDF). It is part of a financial data overview provided by TradingView. The content is primarily a data placeholder, indicating the company's ticker symbol and the market it trades on.", "url": "https://www.tradingview.com/symbols/NASDAQ-CRDF/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:10:20", "published_display": "05 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDF,ANIP Dividends", "summary": "This article provides key financial data for two companies, Cardiff Oncology Inc. (CRDF) and ANI Pharmaceuticals Inc. (ANIP), focusing on their stock performance, market capitalization, income, sales, and various financial ratios. It details current stock prices, recent changes, ", "url": "https://finviz.com/stock?t=CRDF,ANIP&ta=1&p=d&ty=dv&r=m6", "source_name": "Finviz", "published_at": "2026-07-04T17:10:37", "published_display": "04 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDF - Cardiff Oncology Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and a comprehensive financial overview for Cardiff Oncology Inc. (CRDF). It includes key financial metrics such as market cap, enterprise value, income, sales, various ratios, and performance indicators, alongside insider ownership and", "url": "https://finviz.com/stock?t=CRDF&ty=lf", "source_name": "Finviz", "published_at": "2026-07-04T01:10:37", "published_display": "04 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQTWg5Z214MmV5NXBIN2lhcElyNC1QczZIZkQ5emJmNzNMNm9nSXVaVENVbEgtM29JQV9SdnVTNGIxVG5OQUl2UzBxTEtCNkV2VFRBdlZWZFVodUF4RkU4ZUZyYW1zaUpoX3NJZW9aRVM4UWFQOHhoYnhIUDFhRjE5a1V1Z2U2T21icGUxOGZPV05KVno4alZR?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000 Index", "summary": "Cardiff Oncology, Inc. (NasdaqCM: CRDF) has been removed from the Russell 3000 Index, along with several other Russell indices including the Russell Small Cap Comp Growth, Russell 2500 Growth, and Russell 2000 Value benchmarks. The company is a clinical-stage biotechnology firm f", "url": "https://www.marketscreener.com/news/cardiff-oncology-inc-nasdaqcm-crdf-dropped-from-russell-3000-index-ce7f5fdedf80f523", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:39:13", "published_display": "29 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell Small Cap Completeness Index", "summary": "Cardiff Oncology, Inc. (NasdaqCM:CRDF) has been removed from the Russell Small Cap Completeness Index. This news follows a series of announcements indicating the company's removal from several other Russell benchmarks, including the Russell 2500 Growth, Russell 2000 Value, Russel", "url": "https://www.marketscreener.com/news/cardiff-oncology-inc-nasdaqcm-crdf-dropped-from-russell-small-cap-completeness-index-ce7f5fdedf80f123", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T09:41:49", "published_display": "29 Jun 2026 09:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Growth Benchmark", "summary": "Cardiff Oncology, Inc. (NasdaqCM: CRDF) has been removed from the Russell 2000 Growth Benchmark index. This news follows a series of recent changes in the company's index inclusions, as well as several analyst downgrades and financial reports highlighting its performance and stra", "url": "https://www.marketscreener.com/news/cardiff-oncology-inc-nasdaqcm-crdf-dropped-from-russell-2000-growth-benchmark-ce7f5fdedc81f720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:40:33", "published_display": "29 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) CEO makes open-market buy of 24,703 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNRHpuSkw3aFZhVUtEUW5xLWIzNmV5eVFJQzZ5NVN0clEtWUtHTmRjay1XMkhLWkRtQ2U1TEFRenFweU95VklMNXZfMVZGWE42RUh4TXJMV2ZkUnN2NnRpVmw0Q3ZWSHp4WDRORWY0TUxvLTN3ZWQ5VzFFWEpGSnpiaXY0elFId0tUVUNCbWZpZkllNmFUcXVFMG9aYVlSQXFHTFNJbGZJeW1YTVE1WWNSYzNyVTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPSzBMbDJpXzl1dDBxeTFscjlwYlR5djRyZjJmZm9DVHFmQ0IzWkJlZmJBQjFuSHlFZ1JzRWxBWU80VGpVTDFMYjFVaERib3Y5dTR6MFY3ejhWdnhBWkxZVVEwd0NMcFFZeHY5Ni1hcDV4d2VXU2FwcEl0amtaSDNXSW0xVlVzUFpFNU9PM081WmRxUW5rdnJSanp2WnNIZ2c4TEd3NjZoWXJpSnZrQVZUQk9OMjI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director James O. Armitage awarded 40,565 Cardiff Oncology (CRDF) stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNdEQyTUQ2SDVscFN3a2JLNnRZRXZlZGFpdVd5X2lETUNTUlJoSjRnc1l5aUNsMUM0MllRQjBvOFR4d2M0U0xiX2JiYV9TNmFrODczOVAxNFV4MktMM2h5REw0U3gwc3NybkhRVHcwdWUtUUdnUzIyZjl0LV9RX040a3ROUG1RRUJJcDlHOE1ZQkQtVUd3Zll1MjRDc3ZNdFNIM2NVVzhfeWMtbXdGdGFVeUoxSWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Onvansertib Phase 2 results move Cardiff Oncology (NASDAQ: CRDF) toward Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOaGdqeFVsYWdDX0FJV2pIZkpQaW9UOFZoeXlUVlVJdXFhZFZtaFVneHZhWFBpMUtJcmRwWkZnMVBVczRrbVNiNlJYVEdFMjFPWFVkV0N2UXJFODZ3RDlWb3hKaU5tODZpazBfTmN6ZDFkYjk1RlNrdmRHc2NKMGw0dzZ5alFYenlwR3g3NTh2M3ZDT1hRSnRnZnlzZ0VQa2hOc20zQ1ZJbTRBQ3BnNHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiff-oncology-announces-presentation-positive-130600805.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T13:06:00+00:00", "published_display": "02 Jun 2026 13:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiff-oncology-participate-jefferies-global-200100158.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:01:00+00:00", "published_display": "01 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Cardiff Oncology stock rating on license termination", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNYkpqVlNNc1VHb3lRZXluX2h0TVQ2ZTZaa1dTUklFM0prUjM2Nm5CYnk2UmgzYU5CbU4tVTA5dkwwbVFEX0MtOHFZWVk5clhMenNXQ3M0UDZkbXVBQ2F2bWZiMU9BcmRqZUZtZGVJb1BheUJqRnZpWFd2bnZGdkNGcmFwdlhac0pxTVpBbVhiRlBpRDN5d21KRUQzZmZZeFJNNWxUQW0yeDRkSGNGWTNFWGJaT0NGMUM1YWhNeXd3OFBJRWRmdDJqNXdIQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQT3dva1Z1LWdEcGZmemY5Uzg5cTJycU95c0dyU09jbDhYQkNuWUJXTUNuV0U2d1ZlV09fbmEydDhqa21QQXpDU3FHYi1OTEhET2I1cXBRRHMwckg1QnFCRWlrSFY0bTdNbGJ2bW9sYVpaQjZBdGI5LS1CdEpDZ19qUXFlT3NaUTUwSE5MeHI5WHNLTC1KWVdaS2lzWm5rSjl6?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FDA meeting maps Phase 3 test of Cardiff's colorectal cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOb0c4SjdJbFdubGVrT2U1aUpGZmVrWm1rNHE5SjJtaGg0VU9ubk1OVHZTVHNLWGtDXzdITXZwVlVxdEVMX2tKQVFWNE5aZW0wMG9JMXl5T2tSVTNfZmNXNFdLR19NaVl5eXFSN2U2NHhQN3BBWGdYMllERF8yUmhTSlYwSl9lSE01dFA2SXJ1NFY4Z3E0bE90bVJWbkpTaENyUmpTbFBOMWY1Y25HbXl4anFwUF9NT19TNHdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cardiff Oncology overhauls leadership to push cancer drug onvansertib", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNLTNEVXZfamxhaHFYLUd3Rlg2MWdTSE9QSmE1MVRYMVItMTUxeGhMX01PSzhKemE0dnVhbnlRQThxcjhmbHVGdjl5Q3hJWjNocENQZnNTMzVUQ1hPMHBlSENIRmRHdkhpNlBYY3NsTmJUanRDMVl1ZnFlQVZZTzZGSk52X2dhd05LSzRrTUM5UkNGUWlDNEpKQWxuRkdWV2czSzFiblhva1dpWkJmVTB4ZXA5ZlpNQndhNU5xcU1RZ3A?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "StockWatch: C-Suite Shakeup, Phase III Plans Jolt Cardiff Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcnR1ZlhBZk5zUE01dFJxeFN2SUVVV0F3Z1F3Ym9hRXA0Qml1a2xQZVNGTGRpZEZjQmtOdjcwbWEwOF9xU2RULTNvbGZhMnVHc25RM1lRaFNCSjlzd2M4ZGRxRjJjc2hFMXd1bkNhTTE1N2taRkZ3VmhjZEQ5QmNhM1FqUHZua2FNQjhFX1dZR25FZG5ReEpVdVRYeXMzZ2pVeDRIcUM4bXJlNm8?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-02-01T08:00:00+00:00", "published_display": "01 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) Valuation Check After New Onvansertib Phase 2 Data And Leadership Changes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNa3NkcS0ydWVaTG1EMkJrQmgxcjhXeXRZY2V0Yk9NS01zVWFJX3NZaTUtOExmTzdzYng0NDV6eDJvanN0Nl9xU1p4NTA0VDlYSHV6TmdvRURXTVJ2RXJnelk5VjFlNVZadGE2VEtGei1PcDlMUHQxQ1Q5VzA0UGEyMw?oc=5", "source_name": "Market source", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Painful week for individual investors invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) after 11% drop, institutions also suffered losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Stock: Preparing For A Defining 2026 (NASDAQ:CRDF)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxONV9EZ25NM1dicE91M2VkSG94anhueF9lX3dpSUpFRTlvWjlrLUZxZ3BOSlpITGpwY1lSd1N2S0RhbXNPU3dQRVdRX0VYX3lYTUlhVllzbmtvYWpRbjY3dGJqb1dhTHRUZ2xid2hOZkV0b21NemczZlF6aHBhTVQ3RWhiRjZlNVNFbGx6ZllDMk0?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-10-25T07:00:00+00:00", "published_display": "25 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cardiff Oncology (CRDF) Proxy filing Summary", "summary": "Cardiff Oncology (CRDF) has scheduled its annual meeting for June 11, 2026, where shareholders will vote on four key proposals: the election of six directors, the ratification of BDO USA, P.C. as auditor, an amendment to increase shares under the 2021 Equity Incentive Plan, and a", "url": "https://quartr.com/events/cardiff-oncology-crdf-proxy-filing_F9QdsfRX", "source_name": "Quartr", "published_at": "2026-07-17T07:12:10", "published_display": "17 Jul 2026 07:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology CEO Mani Mohindru buys $49,999 of common stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQSmFmN2NJYlVWWDZRNUNIRWlDSXh0TUM1TDRFSWN6RFY3eW1SeEpoeTh6UHRMeHNHb2ZrQzhpVy1KbDBvNUF3T1AxOWpxdmVZUFRzVk5vcFFhRWFuR3VHZ1piR1kzMU9DRmp4WGxBckhRT2txaTJpVjNadGJXQWQ2alNFTENRX1ZMbU5pYlJQZ25DZHRKMXNnaGgzRDl3QWJVb3cxdk9MNlQ4OGxReXU1NDlEWTAwclFneW42YTFRYUJkZy1Z?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T20:30:22+00:00", "published_display": "16 Jul 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cardiff-oncology-insider-bought-shares-200834437.html", "source_name": "MT Newswires", "published_at": "2026-07-16T20:08:34+00:00", "published_display": "16 Jul 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) CEO adds common shares and new warrants stake", "summary": "Cardiff Oncology (CRDF) CEO Mani Mohindru purchased 34,364 common shares on July 14, 2026, at $1.455 per share and acquired an equal number of common stock purchase warrants. These transactions increased her direct holdings to 59,067 common shares and 34,364 warrants. The warrant", "url": "https://www.stocktitan.net/sec-filings/CRDF/form-4-cardiff-oncology-inc-insider-trading-activity-16e458dc03f5.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:09:42", "published_display": "16 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) director buys 687,285 shares and warrants", "summary": "Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases of 687,285 shares of common stock at $1.455 per share and an equal number of common stock purchase warrants with an exercise price of $1.33 per share, dated July 14, 2026. Following these transactions, Pa", "url": "https://www.stocktitan.net/sec-filings/CRDF/form-4-cardiff-oncology-inc-insider-trading-activity-b296479b55c2.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:09:42", "published_display": "16 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cardiff Oncology Inc For: 16 July By Investing.com", "summary": "This article provides a Form 4 filing for Cardiff Oncology Inc. for July 16, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The ar", "url": "https://ca.investing.com/news/stock-market-news/form-4-cardiff-oncology-inc-for-16-july-93CH-4738277", "source_name": "Investing.com Canada", "published_at": "2026-07-16T20:09:42", "published_display": "16 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Raises $10M for Onvansertib Regulatory Push", "summary": "Cardiff Oncology (CRDF) has raised $10 million in a registered direct offering to support regulatory discussions for its lead drug, onvansertib. The drug, an oral PLK1 inhibitor, showed promising Phase II results for RAS-mutated metastatic colorectal cancer, achieving a 72.2% obj", "url": "https://allsci.com/news/funding/public-equity-offerings/cardiff-oncology-raises-usd-10m-ahead-of-regulatory-push-for-onvansertib-in-ras-mutated-colorectal-cancer/", "source_name": "AllSci", "published_at": "2026-07-16T17:09:42", "published_display": "16 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Raises $10.05 Million in Registered Offering; Engages H.C. Wainwright", "summary": "Cardiff Oncology successfully completed a registered equity financing, raising approximately $10.05 million in gross proceeds through the sale of shares and warrants to institutional investors and insiders. The company also engaged H.C. Wainwright as its exclusive placement agent", "url": "https://www.tradingview.com/news/tradingview:ef93d043b1292:0-cardiff-oncology-raises-10-05-million-in-registered-offering-engages-h-c-wainwright/", "source_name": "TradingView", "published_at": "2026-07-16T12:40:38", "published_display": "16 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (Nasdaq: CRDF) closes $10.05M direct offering", "summary": "Cardiff Oncology (Nasdaq: CRDF) has successfully closed a direct offering totaling approximately $10.05 million. The offering involved the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 per share and warrant, with certain officers and directors also p", "url": "https://www.stocktitan.net/sec-filings/CRDF/8-k-cardiff-oncology-inc-reports-material-event-2b72b0890312.html", "source_name": "Stock Titan", "published_at": "2026-07-16T12:40:38", "published_display": "16 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (NASDAQ: CRDF) prices $10.05M share and warrant financing", "summary": "Cardiff Oncology Inc. (NASDAQ: CRDF) has priced a public offering to raise $10.05 million through the sale of common stock and accompanying warrants. The offering includes 9,293,078 shares of common stock and warrants to purchase an equal number of shares, with proceeds designate", "url": "https://www.stocktitan.net/sec-filings/CRDF/424b5-cardiff-oncology-inc-prospectus-supplement-debt-securities-6d756f94ac57.html", "source_name": "Stock Titan", "published_at": "2026-07-16T12:40:38", "published_display": "16 Jul 2026 12:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Announces $10 Million Registered Direct Offering", "summary": "Cardiff Oncology, Inc. has announced a registered direct offering expected to raise approximately $10 million. The offering includes the sale of common stock and accompanying warrants to both institutional investors and certain officers and directors of the company. The net proce", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327673/0/en/Cardiff-Oncology-Announces-10-Million-Registered-Direct-Offering.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T04:09:42", "published_display": "16 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology to Raise $10 Million in Share, Warrant Sale", "summary": "Cardiff Oncology plans to raise $10 million through the sale of shares and warrants to Armistice Capital Master Fund. The company will sell 10 million shares of common stock and warrants to purchase up to 10 million shares at a price of $1.00 per share and accompanying warrant. T", "url": "https://www.moomoo.com/news/post/73012441/cardiff-oncology-to-raise-10-million-in-share-warrant-sale", "source_name": "Moomoo", "published_at": "2026-07-16T02:40:38", "published_display": "16 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital", "summary": "Cardiff Oncology announced a $10 million registered direct offering to bolster its working capital and general corporate purposes. The offering includes common stock and warrants, with participation from company officers and directors. The capital infusion will support the contin", "url": "https://finance.yahoo.com/healthcare/articles/cardiff-oncology-announces-10-million-145406378.html", "source_name": "Market source", "published_at": "2026-07-15T14:54:51", "published_display": "15 Jul 2026 14:54", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology announces $10M direct offering", "summary": "Cardiff Oncology has announced a $10 million registered direct offering. The offering is priced at a premium to the preceding 5-day average closing price of its common stock. This financial move aims to raise capital for the company.", "url": "https://www.msn.com/en-us/money/savingandinvesting/cardiff-oncology-announces-10m-direct-offering/ar-AA27Ydj7?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-07-15T12:12:35", "published_display": "15 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology prices $10M registered direct offering", "summary": "Cardiff Oncology (NASDAQ:CRDF) announced a $10 million registered direct offering, selling over 8.5 million shares and accompanying warrants at $1.05 per share and warrant. Company officers and directors are participating in the offering. The biotech firm plans to use the net pro", "url": "https://www.investing.com/news/company-news/cardiff-oncology-prices-10m-registered-direct-offering-93CH-4793172", "source_name": "Investing.com", "published_at": "2026-07-15T12:12:35", "published_display": "15 Jul 2026 12:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Seeks $10M as Some Officers and Directors Agree to Buy Shares", "summary": "Cardiff Oncology (Nasdaq: CRDF) announced a registered direct offering to raise approximately $10 million by selling 8,571,429 common shares and accompanying warrants at $1.05 per share. Separately, certain officers and directors will purchase 731,707 shares and warrants at $1.43", "url": "https://www.stocktitan.net/news/CRDF/cardiff-oncology-announces-10-million-registered-direct-n63wapgew06g.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:12:35", "published_display": "15 Jul 2026 12:12", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cardiff Oncology, Inc. \u2013 FWB:XE7C", "summary": "The article provides a financial overview of Cardiff Oncology, Inc. (XE7C) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to EBIT forward ratio. It appears to be a stub or placeholder from TradingView, indicating where this financial metric would b", "url": "https://www.tradingview.com/symbols/FWB-XE7C/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T19:39:59", "published_display": "12 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) Noble Capital Markets Emerging Growth Virtual Investor Conference summary", "summary": "Cardiff Oncology (CRDF) summarized their Noble Capital Markets Emerging Growth Virtual Investor Conference, highlighting the promising clinical data for Onvansertib, an oral PLK1 inhibitor, in RAS-mutated metastatic colorectal cancer. The drug showed significant efficacy and tole", "url": "https://quartr.com/events/cardiff-oncology-inc-crdf-noble-capital-markets-emerging-growth-virtual-investor-conference_F9Qde7R0", "source_name": "Quartr", "published_at": "2026-07-08T14:09:28", "published_display": "08 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cardiff Oncology, Inc. \u2013 NASDAQ:CRDF", "summary": "This article provides access to the \"Price to earnings forward\" data for Cardiff Oncology, Inc. (NASDAQ: CRDF) on the TradingView platform. It highlights that the market was closed with no trades recorded at the time of viewing. The content primarily focuses on navigating to the ", "url": "https://www.tradingview.com/symbols/NASDAQ-CRDF/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T01:13:18", "published_display": "08 Jul 2026 01:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cardiff Oncology, Inc. \u2013 TRADEGATE:XE7C", "summary": "The article displays the \"Price to earnings forward\" metric for Cardiff Oncology, Inc. (TRADEGATE:XE7C) on the TradingView platform. It indicates that the market was closed and no trades had occurred for this particular stock. The content primarily focuses on the financial data d", "url": "https://www.tradingview.com/symbols/TRADEGATE-XE7C/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T09:12:24", "published_display": "07 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cardiff Oncology, Inc. \u2013 TRADEGATE:XE7C", "summary": "This article provides financial information for Cardiff Oncology, Inc. (XE7C) on the Tradegate Exchange, specifically focusing on its enterprise value to EBIT forward. The content is presented through TradingView, a platform offering market data and financial tools. It indicates ", "url": "https://www.tradingview.com/symbols/TRADEGATE-XE7C/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T13:41:03", "published_display": "06 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cardiff Oncology, Inc. \u2013 NASDAQ:CRDF", "summary": "This page provides the \"Price to book forward\" financial metric for Cardiff Oncology, Inc. (NASDAQ: CRDF). It states the period, value, and change for this specific financial data point. The content appears to be a data-only entry from TradingView, without additional analytical t", "url": "https://www.tradingview.com/symbols/NASDAQ-CRDF/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T14:12:52", "published_display": "05 Jul 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDF - Cardiff Oncology Inc Dividends", "summary": "This article provides a detailed financial overview of Cardiff Oncology Inc. (CRDF), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short ", "url": "https://finviz.com/stock?t=CRDF&ty=dv", "source_name": "Finviz", "published_at": "2026-07-05T00:12:53", "published_display": "05 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cardiff Oncology, Inc. \u2013 NASDAQ:CRDF", "summary": "This article displays the \"Price to sales forward\" metric for Cardiff Oncology, Inc. (NASDAQ: CRDF). It is part of a financial data overview provided by TradingView. The content is primarily a data placeholder, indicating the company's ticker symbol and the market it trades on.", "url": "https://www.tradingview.com/symbols/NASDAQ-CRDF/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:10:20", "published_display": "05 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDF,ANIP Dividends", "summary": "This article provides key financial data for two companies, Cardiff Oncology Inc. (CRDF) and ANI Pharmaceuticals Inc. (ANIP), focusing on their stock performance, market capitalization, income, sales, and various financial ratios. It details current stock prices, recent changes, ", "url": "https://finviz.com/stock?t=CRDF,ANIP&ta=1&p=d&ty=dv&r=m6", "source_name": "Finviz", "published_at": "2026-07-04T17:10:37", "published_display": "04 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDF - Cardiff Oncology Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and a comprehensive financial overview for Cardiff Oncology Inc. (CRDF). It includes key financial metrics such as market cap, enterprise value, income, sales, various ratios, and performance indicators, alongside insider ownership and", "url": "https://finviz.com/stock?t=CRDF&ty=lf", "source_name": "Finviz", "published_at": "2026-07-04T01:10:37", "published_display": "04 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQTWg5Z214MmV5NXBIN2lhcElyNC1QczZIZkQ5emJmNzNMNm9nSXVaVENVbEgtM29JQV9SdnVTNGIxVG5OQUl2UzBxTEtCNkV2VFRBdlZWZFVodUF4RkU4ZUZyYW1zaUpoX3NJZW9aRVM4UWFQOHhoYnhIUDFhRjE5a1V1Z2U2T21icGUxOGZPV05KVno4alZR?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000 Index", "summary": "Cardiff Oncology, Inc. (NasdaqCM: CRDF) has been removed from the Russell 3000 Index, along with several other Russell indices including the Russell Small Cap Comp Growth, Russell 2500 Growth, and Russell 2000 Value benchmarks. The company is a clinical-stage biotechnology firm f", "url": "https://www.marketscreener.com/news/cardiff-oncology-inc-nasdaqcm-crdf-dropped-from-russell-3000-index-ce7f5fdedf80f523", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:39:13", "published_display": "29 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell Small Cap Completeness Index", "summary": "Cardiff Oncology, Inc. (NasdaqCM:CRDF) has been removed from the Russell Small Cap Completeness Index. This news follows a series of announcements indicating the company's removal from several other Russell benchmarks, including the Russell 2500 Growth, Russell 2000 Value, Russel", "url": "https://www.marketscreener.com/news/cardiff-oncology-inc-nasdaqcm-crdf-dropped-from-russell-small-cap-completeness-index-ce7f5fdedf80f123", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T09:41:49", "published_display": "29 Jun 2026 09:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Growth Benchmark", "summary": "Cardiff Oncology, Inc. (NasdaqCM: CRDF) has been removed from the Russell 2000 Growth Benchmark index. This news follows a series of recent changes in the company's index inclusions, as well as several analyst downgrades and financial reports highlighting its performance and stra", "url": "https://www.marketscreener.com/news/cardiff-oncology-inc-nasdaqcm-crdf-dropped-from-russell-2000-growth-benchmark-ce7f5fdedc81f720", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:40:33", "published_display": "29 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) CEO makes open-market buy of 24,703 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNRHpuSkw3aFZhVUtEUW5xLWIzNmV5eVFJQzZ5NVN0clEtWUtHTmRjay1XMkhLWkRtQ2U1TEFRenFweU95VklMNXZfMVZGWE42RUh4TXJMV2ZkUnN2NnRpVmw0Q3ZWSHp4WDRORWY0TUxvLTN3ZWQ5VzFFWEpGSnpiaXY0elFId0tUVUNCbWZpZkllNmFUcXVFMG9aYVlSQXFHTFNJbGZJeW1YTVE1WWNSYzNyVTg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPSzBMbDJpXzl1dDBxeTFscjlwYlR5djRyZjJmZm9DVHFmQ0IzWkJlZmJBQjFuSHlFZ1JzRWxBWU80VGpVTDFMYjFVaERib3Y5dTR6MFY3ejhWdnhBWkxZVVEwd0NMcFFZeHY5Ni1hcDV4d2VXU2FwcEl0amtaSDNXSW0xVlVzUFpFNU9PM081WmRxUW5rdnJSanp2WnNIZ2c4TEd3NjZoWXJpSnZrQVZUQk9OMjI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director James O. Armitage awarded 40,565 Cardiff Oncology (CRDF) stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNdEQyTUQ2SDVscFN3a2JLNnRZRXZlZGFpdVd5X2lETUNTUlJoSjRnc1l5aUNsMUM0MllRQjBvOFR4d2M0U0xiX2JiYV9TNmFrODczOVAxNFV4MktMM2h5REw0U3gwc3NybkhRVHcwdWUtUUdnUzIyZjl0LV9RX040a3ROUG1RRUJJcDlHOE1ZQkQtVUd3Zll1MjRDc3ZNdFNIM2NVVzhfeWMtbXdGdGFVeUoxSWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Onvansertib Phase 2 results move Cardiff Oncology (NASDAQ: CRDF) toward Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOaGdqeFVsYWdDX0FJV2pIZkpQaW9UOFZoeXlUVlVJdXFhZFZtaFVneHZhWFBpMUtJcmRwWkZnMVBVczRrbVNiNlJYVEdFMjFPWFVkV0N2UXJFODZ3RDlWb3hKaU5tODZpazBfTmN6ZDFkYjk1RlNrdmRHc2NKMGw0dzZ5alFYenlwR3g3NTh2M3ZDT1hRSnRnZnlzZ0VQa2hOc20zQ1ZJbTRBQ3BnNHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiff-oncology-announces-presentation-positive-130600805.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T13:06:00+00:00", "published_display": "02 Jun 2026 13:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiff-oncology-participate-jefferies-global-200100158.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:01:00+00:00", "published_display": "01 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts Cardiff Oncology stock rating on license termination", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNYkpqVlNNc1VHb3lRZXluX2h0TVQ2ZTZaa1dTUklFM0prUjM2Nm5CYnk2UmgzYU5CbU4tVTA5dkwwbVFEX0MtOHFZWVk5clhMenNXQ3M0UDZkbXVBQ2F2bWZiMU9BcmRqZUZtZGVJb1BheUJqRnZpWFd2bnZGdkNGcmFwdlhac0pxTVpBbVhiRlBpRDN5d21KRUQzZmZZeFJNNWxUQW0yeDRkSGNGWTNFWGJaT0NGMUM1YWhNeXd3OFBJRWRmdDJqNXdIQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQT3dva1Z1LWdEcGZmemY5Uzg5cTJycU95c0dyU09jbDhYQkNuWUJXTUNuV0U2d1ZlV09fbmEydDhqa21QQXpDU3FHYi1OTEhET2I1cXBRRHMwckg1QnFCRWlrSFY0bTdNbGJ2bW9sYVpaQjZBdGI5LS1CdEpDZ19qUXFlT3NaUTUwSE5MeHI5WHNLTC1KWVdaS2lzWm5rSjl6?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA meeting maps Phase 3 test of Cardiff's colorectal cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOb0c4SjdJbFdubGVrT2U1aUpGZmVrWm1rNHE5SjJtaGg0VU9ubk1OVHZTVHNLWGtDXzdITXZwVlVxdEVMX2tKQVFWNE5aZW0wMG9JMXl5T2tSVTNfZmNXNFdLR19NaVl5eXFSN2U2NHhQN3BBWGdYMllERF8yUmhTSlYwSl9lSE01dFA2SXJ1NFY4Z3E0bE90bVJWbkpTaENyUmpTbFBOMWY1Y25HbXl4anFwUF9NT19TNHdn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology overhauls leadership to push cancer drug onvansertib", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNLTNEVXZfamxhaHFYLUd3Rlg2MWdTSE9QSmE1MVRYMVItMTUxeGhMX01PSzhKemE0dnVhbnlRQThxcjhmbHVGdjl5Q3hJWjNocENQZnNTMzVUQ1hPMHBlSENIRmRHdkhpNlBYY3NsTmJUanRDMVl1ZnFlQVZZTzZGSk52X2dhd05LSzRrTUM5UkNGUWlDNEpKQWxuRkdWV2czSzFiblhva1dpWkJmVTB4ZXA5ZlpNQndhNU5xcU1RZ3A?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: C-Suite Shakeup, Phase III Plans Jolt Cardiff Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcnR1ZlhBZk5zUE01dFJxeFN2SUVVV0F3Z1F3Ym9hRXA0Qml1a2xQZVNGTGRpZEZjQmtOdjcwbWEwOF9xU2RULTNvbGZhMnVHc25RM1lRaFNCSjlzd2M4ZGRxRjJjc2hFMXd1bkNhTTE1N2taRkZ3VmhjZEQ5QmNhM1FqUHZua2FNQjhFX1dZR25FZG5ReEpVdVRYeXMzZ2pVeDRIcUM4bXJlNm8?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-02-01T08:00:00+00:00", "published_display": "01 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) Valuation Check After New Onvansertib Phase 2 Data And Leadership Changes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNa3NkcS0ydWVaTG1EMkJrQmgxcjhXeXRZY2V0Yk9NS01zVWFJX3NZaTUtOExmTzdzYng0NDV6eDJvanN0Nl9xU1p4NTA0VDlYSHV6TmdvRURXTVJ2RXJnelk5VjFlNVZadGE2VEtGei1PcDlMUHQxQ1Q5VzA0UGEyMw?oc=5", "source_name": "Market source", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Painful week for individual investors invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) after 11% drop, institutions also suffered losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiff Oncology Stock: Preparing For A Defining 2026 (NASDAQ:CRDF)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxONV9EZ25NM1dicE91M2VkSG94anhueF9lX3dpSUpFRTlvWjlrLUZxZ3BOSlpITGpwY1lSd1N2S0RhbXNPU3dQRVdRX0VYX3lYTUlhVllzbmtvYWpRbjY3dGJqb1dhTHRUZ2xid2hOZkV0b21NemczZlF6aHBhTVQ3RWhiRjZlNVNFbGx6ZllDMk0?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-10-25T07:00:00+00:00", "published_display": "25 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 54, "sentiment_summary": {"positive": 10, "negative": 10, "neutral": 34, "score": 50, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 20.7, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 0.88, "latest_week": "2026-07-17", "one_week_move": -33.8, "four_week_move": -27.3, "twelve_week_move": -48.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.446943, "market_dynamics_buy_signal": false, "relative_strength": -61.628908, "fair_value_gap": -65.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 52.1475, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-33.8% over one week, -27.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 8}, {"label": "simplywall.st", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "www.marketscreener.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-33.8% over one week, -27.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Cardiff Oncology (CRDF) Proxy filing Summary"}], "updated_at": "2026-07-23T07:08:54.145056+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}